Of Counsel Margaret G. Nelson was quoted in a Bloomberg Law article, “SEC Accounting-Enforcement Cases Tumble in 2018,” about a drop in the overall number of financial reporting related cases this year compared to 2017.
Nelson said accounting fraud cases are very complex and can take a long time to process. Auditor-focused cases have also dropped, she said, even though SEC officials say that gatekeepers, including auditors, remain a focus.
“We saw plenty of fraud cases or material misstatement cases brought against the issuer,” she said. “But you didn’t see a companion case brought against the auditor.”
(Subscription required.)
Nelson said accounting fraud cases are very complex and can take a long time to process. Auditor-focused cases have also dropped, she said, even though SEC officials say that gatekeepers, including auditors, remain a focus.
“We saw plenty of fraud cases or material misstatement cases brought against the issuer,” she said. “But you didn’t see a companion case brought against the auditor.”
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”